No Relief In Sight For Future Of OTC Asthma Products

The slated removal of OTC epinephrine inhalers from the market in 28 months raises questions about whether affordable alternatives will be available and whether FDA would approve another nonprescription asthma drug

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet